pyrazines has been researched along with p5091 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
Gu, W; Sun, H; Tavana, O | 1 |
2 other study(ies) available for pyrazines and p5091
Article | Year |
---|---|
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
Targeting HAUSP in both p53 wildtype and p53-mutant tumors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Imidazoles; Indenes; Molecular Targeted Therapy; N-Myc Proto-Oncogene Protein; Neurons; Piperazines; Protease Inhibitors; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrazines; RNA, Small Interfering; Signal Transduction; Thiophenes; Tumor Suppressor Protein p53; Ubiquitin-Specific Peptidase 7 | 2018 |